Integrated Investment Consultants LLC Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Integrated Investment Consultants LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.2% in the 4th quarter, HoldingsChannel reports. The firm owned 19,773 shares of the pharmaceutical company’s stock after purchasing an additional 39 shares during the period. Integrated Investment Consultants LLC’s holdings in Vertex Pharmaceuticals were worth $7,963,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Arkadios Wealth Advisors boosted its position in shares of Vertex Pharmaceuticals by 61.1% during the 4th quarter. Arkadios Wealth Advisors now owns 1,081 shares of the pharmaceutical company’s stock worth $435,000 after purchasing an additional 410 shares in the last quarter. InTrack Investment Management Inc lifted its stake in shares of Vertex Pharmaceuticals by 49.9% in the fourth quarter. InTrack Investment Management Inc now owns 2,132 shares of the pharmaceutical company’s stock valued at $878,000 after purchasing an additional 710 shares during the period. TrueWealth Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 35.4% in the fourth quarter. TrueWealth Advisors LLC now owns 1,037 shares of the pharmaceutical company’s stock valued at $418,000 after purchasing an additional 271 shares during the period. Arthur M. Cohen & Associates LLC boosted its holdings in Vertex Pharmaceuticals by 3.5% during the fourth quarter. Arthur M. Cohen & Associates LLC now owns 890 shares of the pharmaceutical company’s stock worth $358,000 after buying an additional 30 shares in the last quarter. Finally, Brooklyn Investment Group increased its holdings in Vertex Pharmaceuticals by 1.8% in the fourth quarter. Brooklyn Investment Group now owns 1,906 shares of the pharmaceutical company’s stock valued at $768,000 after buying an additional 33 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ:VRTX opened at $422.00 on Friday. The business’s 50-day simple moving average is $442.83 and its 200 day simple moving average is $466.48. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm earned $3.67 earnings per share. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Oppenheimer lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. UBS Group boosted their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. dropped their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, December 23rd. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.